BACKGROUND: Cord blood provides haematopoietic stem cells for allogeneic transplantation and, thanks to the naivety of its immune system, has several advantages over other sources of stem cells. In the transplantation setting, the presence of immunosuppressive human leucocyte antigen (HLA)-G molecules has been advocated to prevent both rejection and Graft-versus-Host disease. HLA-G is physiologically expressed throughout pregnancy and is contained in cord blood at birth. Moreover, it has recently been reported that not only cord blood mesenchymal cells, but also CD34+ cell progenies produce soluble HLA-G (sHLA-G). We tried to identify the largest producer of sHLA-G among 85 healthy cord blood donors at Pavia Cord Blood Bank, correlating the sHLA-G concentration with the HLA-G 14bp insertion/deletion (INS/DEL) genotype and CD34+ cell concentration. MATERIALS AND METHODS: We measured sHLA-G levels in 36 cord blood plasma stored at -20 °C for 2 months and 49 cord blood plasma stored at -196 °C for 4-6 years, by enzyme-linked immunosorbent assay. All cord blood donors were genotyped for the HLA-G 14bp INS/DEL polymorphism by polymerase chain reaction. For each cord blood unit, we measured the cell concentration by flow cytometry. RESULTS: We did not find differences in sHLA-G levels between cord blood plasma aliquots stored for 4-6 years at -196 °C and cord blood plasma aliquots stored for 2 months at -20 °C. We observed a higher sHLA-G concentration in cord blood plasma donors who carried the HLA-G 14bp INS/INS genotype and had higher CD34+ cell concentrations (P=0.006). DISCUSSION: This is the first report showing that the best cord blood stem cell donor is also the best sHLA-G producer, particularly if genetically characterized by the HLA-G 14bp INS/INS genotype. If the therapeutic role of sHLA-G molecules were to be finally established in the transplantation setting, our data suggest that cord blood plasma donors can provide a safe source of allogeneic sHLA-G immunosuppressive molecules ready for transfusion.
BACKGROUND: Cord blood provides haematopoietic stem cells for allogeneic transplantation and, thanks to the naivety of its immune system, has several advantages over other sources of stem cells. In the transplantation setting, the presence of immunosuppressive humanleucocyte antigen (HLA)-G molecules has been advocated to prevent both rejection and Graft-versus-Host disease. HLA-G is physiologically expressed throughout pregnancy and is contained in cord blood at birth. Moreover, it has recently been reported that not only cord blood mesenchymal cells, but also CD34+ cell progenies produce soluble HLA-G (sHLA-G). We tried to identify the largest producer of sHLA-G among 85 healthy cord blood donors at Pavia Cord Blood Bank, correlating the sHLA-G concentration with the HLA-G 14bp insertion/deletion (INS/DEL) genotype and CD34+ cell concentration. MATERIALS AND METHODS: We measured sHLA-G levels in 36 cord blood plasma stored at -20 °C for 2 months and 49 cord blood plasma stored at -196 °C for 4-6 years, by enzyme-linked immunosorbent assay. All cord blood donors were genotyped for the HLA-G14bp INS/DEL polymorphism by polymerase chain reaction. For each cord blood unit, we measured the cell concentration by flow cytometry. RESULTS: We did not find differences in sHLA-G levels between cord blood plasma aliquots stored for 4-6 years at -196 °C and cord blood plasma aliquots stored for 2 months at -20 °C. We observed a higher sHLA-G concentration in cord blood plasma donors who carried the HLA-G14bp INS/INS genotype and had higher CD34+ cell concentrations (P=0.006). DISCUSSION: This is the first report showing that the best cord blood stem cell donor is also the best sHLA-G producer, particularly if genetically characterized by the HLA-G14bp INS/INS genotype. If the therapeutic role of sHLA-G molecules were to be finally established in the transplantation setting, our data suggest that cord blood plasma donors can provide a safe source of allogeneic sHLA-G immunosuppressive molecules ready for transfusion.
Authors: Jürgen Zingsem; Erwin Strasser; Volker Weisbach; Robert Zimmermann; Jürgen Ringwald; Tamme Goecke; Matthias Wilhelm Beckmann; Reinhold Eckstein Journal: Transfusion Date: 2003-06 Impact factor: 3.157
Authors: J W Gratama; A Orfao; D Barnett; B Brando; A Huber; G Janossy; H E Johnsen; M Keeney; G E Marti; F Preijers; G Rothe; S Serke; D R Sutherland; C E Van der Schoot; G Schmitz; S Papa Journal: Cytometry Date: 1998-06-15
Authors: J C O Crispim; R A Duarte; C P Soares; R Costa; J S Silva; C T Mendes-Júnior; I J Wastowski; L P Faggioni; L T Saber; E A Donadi Journal: Transpl Immunol Date: 2007-11-26 Impact factor: 1.708
Authors: Vera Rebmann; Diana Bartsch; Andreas Wunsch; Petra Möllenbeck; Thomas Golda; Richard Viebahn; Hans Grosse-Wilde Journal: Hum Immunol Date: 2009-08-06 Impact factor: 2.850
Authors: A Le Maux; G Noël; B Birebent; J-M Grosset; N Vu; S De Guibert; M Bernard; G Semana; L Amiot Journal: Clin Exp Immunol Date: 2008-01-28 Impact factor: 4.330
Authors: Maria Loustau; François Anna; Raphaelle Dréan; Martin Lecomte; Pierre Langlade-Demoyen; Julien Caumartin Journal: Front Immunol Date: 2020-08-14 Impact factor: 7.561